Apimeds Pharmaceuticals US, Inc.
No SEC Form 4 filings for $APUS in the last 30 days.
See all $APUS insider activity →Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company, Erik Emerson, Lokahi Therapeutic
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “ Assignment Agreement ”) with FreeT Inc., a comp
Premarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning APUS (Apimeds Pharmaceuticals US, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent APUS coverage spans financial news, corporate actions and market movers.
Board composition change may affect governance and future strategic direction, but no immediate financial impact disclosed.
The assignment could boost future revenue streams from Korean clinics and US royalties, but immediate financial impact is limited.
Pharma micro‑cap declines; no catalyst.
APUS has filed for a five-day extension to submit its Q1 2026 financial report, citing the need for additional time. No significant operational changes are expected.
The noncompliance notice from NYSE American indicates regulatory and operational risks for Apimeds Pharmaceuticals US. The company's failure to file its 2025 Form 10-K and the ongoing trading halt suggest potential negative market perception, likely leading to a decline in stock price in the short term.
AlphAI scores every news story that mentions APUS with an AI model for sentiment and relevance, and aggregates insider trades from Apimeds Pharmaceuticals US, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company, Erik Emerson, Lokahi Therapeutic
1 min readApimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “ Assignment Agreement ”) with FreeT Inc., a comp
2 min readPremarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
1 min readApimeds Pharmaceuticals US, Inc. (APUS) has filed a Form NT 10-Q with the SEC, indicating that it will be submitting its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, late. The company stated it requires additional time to finalize its financial statements and expects to file the report within the five-calendar-day extension period permitted under Rule 12b-25. No significant change in the results of operations from the corresponding period for the last fiscal year is anticipated.
2 min readApimeds Pharmaceuticals US (APUS) received a notice of noncompliance from NYSE American on April 17, 2026, for failing to file its 2025 Form 10-K. The company has a six-month cure period, remains listed with a ".LF" designation, and its trading halt from April 2, 2026, is still in effect.
2 min readApimeds Pharmaceuticals US, Inc. (APUS) has filed a Form 12b-25 notification with the SEC, indicating that it will be late in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company requires additional time to complete financial statements and for its independent auditor to finalize the review and audit. APUS anticipates filing the 10-K within the fifteen-day grace period allowed by Rule 12b-25.
2 min readHopewell, New Jersey, May 12, 2025 ( GLOBE NEWSWIRE ) -- Apimeds Pharmaceuticals US, Inc. ( NYSE American: APUS ) ( "Apimeds" or the "Company" ) , a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which ...
4 min read
